01
A proteomic map of pathological tau separates dementia-associated tauopathies. Its most compelling result lives in brain tissue—not yet in the clinic.
What changedThe team mapped 145 post-translational modifications and 195 cleavage sites, then tested whether those molecular patterns could distinguish disease groups.
Where it stopsNo blood test. No diagnosis in living patients. No validated drug target.